Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes

Research output: Contribution to journalArticle

Abstract

Farnesyltransferase inhibitors were initially developed as Ras inhibitors as they inhibit the prenylation necessary for Ras activation. It is clear now that their mechanism of action is more complex and probably involves other proteins unrelated to Ras. At least 3 drugs within this family have been investigated in acute myeloid leukemia, myelodysplastic syndromes, and other leukemias. These are tipifarnib (R115777, Zarnestra®), lonafarnib (SCH66336, Sarasar™), and BMS-214662. The first 2 are administered orally, whereas BMS-214662 is given intravenously. These drugs are at different stages of development, and design of treatment schedules and methodology of the available studies are very different. Although most of the information is still preliminary, these agents have demonstrated clear evidence of clinical activity in these diseases and very favorable toxicity profiles. Several studies are still ongoing to better define the efficacy of these agents in the treatment of leukemias, as well as to determine the best schedules, the role of combination with other agents, and the role of these agents in different settings, such as the management of minimal residual disease. It is very possible that these agents will soon find their way to the ranks of established agents for the management of myeloid malignancies.

Original languageEnglish (US)
Pages (from-to)S30-S35
JournalClinical Lymphoma
Volume4
Issue numberSUPPL. 1
DOIs
StatePublished - Aug 2003
Externally publishedYes

Fingerprint

tipifarnib
Farnesyltranstransferase
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Appointments and Schedules
Leukemia
Prenylation
Residual Neoplasm
Pharmaceutical Preparations
Neoplasms
Proteins
7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine
lonafarnib

Keywords

  • Acute myeloid lymphoma
  • BMS-214662
  • Geranylgeranyl transferase
  • Lonafarnib
  • Prenylation
  • Ras pathway
  • Tipifarnib

ASJC Scopus subject areas

  • Cancer Research

Cite this

Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. / Cortes, Jorge.

In: Clinical Lymphoma, Vol. 4, No. SUPPL. 1, 08.2003, p. S30-S35.

Research output: Contribution to journalArticle

@article{07a8f6b252e347f394452cf1963c69a2,
title = "Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes",
abstract = "Farnesyltransferase inhibitors were initially developed as Ras inhibitors as they inhibit the prenylation necessary for Ras activation. It is clear now that their mechanism of action is more complex and probably involves other proteins unrelated to Ras. At least 3 drugs within this family have been investigated in acute myeloid leukemia, myelodysplastic syndromes, and other leukemias. These are tipifarnib (R115777, Zarnestra{\circledR}), lonafarnib (SCH66336, Sarasar™), and BMS-214662. The first 2 are administered orally, whereas BMS-214662 is given intravenously. These drugs are at different stages of development, and design of treatment schedules and methodology of the available studies are very different. Although most of the information is still preliminary, these agents have demonstrated clear evidence of clinical activity in these diseases and very favorable toxicity profiles. Several studies are still ongoing to better define the efficacy of these agents in the treatment of leukemias, as well as to determine the best schedules, the role of combination with other agents, and the role of these agents in different settings, such as the management of minimal residual disease. It is very possible that these agents will soon find their way to the ranks of established agents for the management of myeloid malignancies.",
keywords = "Acute myeloid lymphoma, BMS-214662, Geranylgeranyl transferase, Lonafarnib, Prenylation, Ras pathway, Tipifarnib",
author = "Jorge Cortes",
year = "2003",
month = "8",
doi = "10.3816/CLM.2003.s.006",
language = "English (US)",
volume = "4",
pages = "S30--S35",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes

AU - Cortes, Jorge

PY - 2003/8

Y1 - 2003/8

N2 - Farnesyltransferase inhibitors were initially developed as Ras inhibitors as they inhibit the prenylation necessary for Ras activation. It is clear now that their mechanism of action is more complex and probably involves other proteins unrelated to Ras. At least 3 drugs within this family have been investigated in acute myeloid leukemia, myelodysplastic syndromes, and other leukemias. These are tipifarnib (R115777, Zarnestra®), lonafarnib (SCH66336, Sarasar™), and BMS-214662. The first 2 are administered orally, whereas BMS-214662 is given intravenously. These drugs are at different stages of development, and design of treatment schedules and methodology of the available studies are very different. Although most of the information is still preliminary, these agents have demonstrated clear evidence of clinical activity in these diseases and very favorable toxicity profiles. Several studies are still ongoing to better define the efficacy of these agents in the treatment of leukemias, as well as to determine the best schedules, the role of combination with other agents, and the role of these agents in different settings, such as the management of minimal residual disease. It is very possible that these agents will soon find their way to the ranks of established agents for the management of myeloid malignancies.

AB - Farnesyltransferase inhibitors were initially developed as Ras inhibitors as they inhibit the prenylation necessary for Ras activation. It is clear now that their mechanism of action is more complex and probably involves other proteins unrelated to Ras. At least 3 drugs within this family have been investigated in acute myeloid leukemia, myelodysplastic syndromes, and other leukemias. These are tipifarnib (R115777, Zarnestra®), lonafarnib (SCH66336, Sarasar™), and BMS-214662. The first 2 are administered orally, whereas BMS-214662 is given intravenously. These drugs are at different stages of development, and design of treatment schedules and methodology of the available studies are very different. Although most of the information is still preliminary, these agents have demonstrated clear evidence of clinical activity in these diseases and very favorable toxicity profiles. Several studies are still ongoing to better define the efficacy of these agents in the treatment of leukemias, as well as to determine the best schedules, the role of combination with other agents, and the role of these agents in different settings, such as the management of minimal residual disease. It is very possible that these agents will soon find their way to the ranks of established agents for the management of myeloid malignancies.

KW - Acute myeloid lymphoma

KW - BMS-214662

KW - Geranylgeranyl transferase

KW - Lonafarnib

KW - Prenylation

KW - Ras pathway

KW - Tipifarnib

UR - http://www.scopus.com/inward/record.url?scp=0142061051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142061051&partnerID=8YFLogxK

U2 - 10.3816/CLM.2003.s.006

DO - 10.3816/CLM.2003.s.006

M3 - Article

C2 - 14556673

AN - SCOPUS:0142061051

VL - 4

SP - S30-S35

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - SUPPL. 1

ER -